Vivani Medical, Inc. filings document a clinical-stage company with Nasdaq-listed common stock and development activities in NanoPortal™ drug implants and Cortigent neurostimulation devices. Recent Form 8-K reports cover operating results, Regulation FD corporate presentations, material definitive agreements, registered direct offerings and private placements that affect common-stock capital structure.
Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting procedures and other governance matters. The filing record also includes formal disclosures tied to clinical and business updates for Vivani’s semaglutide implant candidates and corporate-structure matters involving its wholly owned Cortigent subsidiary, including the Orion® Visual Cortical Prosthesis System.
Vivani Medical, Inc. director Alexandra L. Popoff received an annual non-qualified stock option grant covering 36,516 shares of common stock at an exercise price of $1.22 per share. The option expires on June 23, 2036 and vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to continued service. Following this grant, she holds 36,516 options directly under this award.
Vivani Medical, Inc. director Daniel Bradbury received an annual grant of non-qualified stock options as part of the company’s Non-Employee Director Compensation Policy. The award covers 36,516 options to buy common stock at an exercise price of $1.22 per share, representing 36,516 underlying shares.
The option vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to his continued service as a director. Following this grant, Bradbury holds 36,516 options, and the options are scheduled to expire on June 23, 2036.
Vivani Medical, Inc. director Aaron Mendelsohn received a grant of stock options as part of his non-employee director compensation. He was awarded a non-qualified option covering 36,516 shares of common stock at an exercise price of $1.22 per share, held directly.
The option vests in full on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, contingent on continued board service through that date, and expires on June 23, 2036. This is a compensation-related award, not an open-market stock purchase or sale.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported a significant insider purchase of the company’s common stock. He acquired 1,587,301 shares in a private sale at $1.26 per share under a Share Purchase Agreement dated as of August 11, 2025, for gross transaction value of $1,999,999.26. Following this transaction, he beneficially owns 40,918,286 shares of Vivani common stock directly and through several trusts and LLCs over which he has voting and dispositive power.
Vivani Medical, Inc. is providing an informational update by sharing an investor slide presentation in connection with its appearance at the Jefferies Global Healthcare Conference in New York. The company plans to present on June 4, 2026 at 11:05 a.m. Eastern, and the slides are available as Exhibit 99.1 and on the Investors section of its website.
The company notes that the slide deck speaks only as of its date and that Vivani has no obligation to update it, even if circumstances change. The information in this communication is being furnished under Regulation FD and is not deemed filed for liability purposes under the securities laws.
Vivani Medical’s largest shareholder, Gregg Williams, filed Amendment No. 11 to his Schedule 13D, reporting beneficial ownership of 43,218,497 shares of common stock, or 47.1% of the company’s outstanding shares. This total includes shares held through several family trusts and LLCs, as well as warrants and stock options exercisable within 60 days of May 15, 2026.
Williams, together with related entities, acquired the shares for investment purposes and is deemed to control the company due to his board role and ownership level. The filing details multiple recent and ongoing share purchases by the Gregg G. Williams 2006 Trust, including structured purchase agreements with the company at prices between $0.98 and $1.62 per share, some with closings scheduled through July 15, 2026.
Vivani Medical, Inc. director and significant shareholder Gregg Williams bought 1,587,301 shares of common stock at $1.26 per share in a private sale transaction. The footnotes state the gross amount for this transaction was $1,999,999.26.
After these transactions, Williams is reported as owning a total of 39,330,985 Vivani shares directly and indirectly. This includes 4,799,200 shares held personally and additional holdings through several trusts and LLCs over which he has voting and dispositive power.
Vivani Medical reported first quarter 2026 results, highlighting a net loss of $6.8 million compared with $6.3 million a year earlier, and ending the period with $19.7 million in cash and cash equivalents. Total assets were $42.4 million and stockholders’ equity was $19.1 million.
Operating expenses rose modestly as research and development reached $4.4 million and general and administrative expenses were $2.4 million, each up about 4% year over year. The company used $6.2 million in operating cash during the quarter and raised $9.7 million through a registered direct offering and other securities purchase agreements, contributing to an expected cash runway through the first half of 2027 while it advances its GLP‑1 implant SLIM‑1 Phase 1 trial and prepares a potential Phase 2 study.
Vivani Medical reported a net loss of $6.8 million for the quarter ended March 31, 2026, slightly higher than the $6.3 million loss a year earlier as it advanced its clinical-stage implant programs.
Research and development expenses were $4.4 million and general and administrative costs were $2.4 million, both up about 4% year over year. Cash, cash equivalents and restricted cash totaled $21.1 million, including $19.7 million of cash and cash equivalents, supported by $9.7 million of net financing inflows in the quarter from private sales and a registered direct offering.
The company estimates its current capital, plus remaining committed equity financings, can fund operations into mid‑2027, but additional capital will be needed beyond that as it continues developing its NanoPortal-based GLP‑1 implant candidates and works to separate its Cortigent neurostimulation business.